<DOC>
	<DOC>NCT00987870</DOC>
	<brief_summary>This study will determine the efficacy of topical BFH772 in psoriasis patients and the safety after multiple dosing.</brief_summary>
	<brief_title>Safety and Efficacy of BFH772 in Psoriasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Stable mild to moderate plaque psoriasis (BSA involvement &lt; 10% or PASI &lt; 10 Category "mild to moderate" on PGA as according to the EMEA (CHMP 2004) (Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis), with or without arthritis Diagnosed or history of psoriasis for at least 6 months prior to screening Nonplaque forms of psoriasis Druginduced psoriasis Current use of beta blockers Congestive heart failure (NYHA &gt;III), QT interval &gt;450msec or poorly controlled diabetes mellitus Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Stable plaque Psoriasis</keyword>
	<keyword>inflammatory skin</keyword>
	<keyword>with or without arthritis</keyword>
</DOC>